Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes
- PMID:12200198
- DOI: 10.1016/s0892-0362(02)00221-0
Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes
Abstract
In Parkinson's disease (PD), therapies to delay or suppress the progression of cell death in nigrostriatal dopamine neurons have been proposed by use of various agents. An inhibitor of type B monoamine oxidase (MAO-B), (-)deprenyl (selegiline), was reported to have neuroprotective activity, but clinical trials failed to confirm it. However, the animal and cellular models of PD proved that selegiline protects neurons from cell death. Among selegiline-related propargylamines, (R)(+)-N-propargyl-1-aminoindan (rasagiline) was the most effective to suppress the cell death in in vivo and in vitro experiments. In this paper, the mechanism of the neuroprotection by rasagiline was examined using human dopaminergic SH-SY5Y cells against cell death induced by an endogenous dopaminergic neurotoxin N-methyl(R)salsolinol (NM(R)Sal). NM(R)Sal induced apoptosis (but not necrosis) in SH-SY5Y cells, and the apoptotic cascade was initiated by mitochondrial permeability transition (PT) and activated by stepwise reactions. Rasagiline prevented the PT in mitochondria directly and also indirectly through induction of antiapoptotic Bcl-2 and a neurotrophic factor, glial cell line-derived neurotrophic factor (GDNF). Long-term administration of propargylamines to rats increased the activities of antioxidative enzymes superoxide dismutase (SOD) and catalase in the brain regions containing dopamine neurons. Rasagiline and related propargylamines may rescue degenerating dopamine neurons through inhibiting death signal transduction initiated by mitochondria PT.
Similar articles
- Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease.Naoi M, Maruyama W.Naoi M, et al.Expert Rev Neurother. 2009 Aug;9(8):1233-50. doi: 10.1586/ern.09.68.Expert Rev Neurother. 2009.PMID:19673610
- Neurotoxins induce apoptosis in dopamine neurons: protection by N-propargylamine-1(R)- and (S)-aminoindan, rasagiline and TV1022.Maruyama W, Akao Y, Youdim MB, Naoi M.Maruyama W, et al.J Neural Transm Suppl. 2000;(60):171-86. doi: 10.1007/978-3-7091-6301-6_11.J Neural Transm Suppl. 2000.PMID:11205138
- N-Propargylamine protects SH-SY5Y cells from apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, through stabilization of mitochondrial membrane and induction of anti-apoptotic Bcl-2.Yi H, Maruyama W, Akao Y, Takahashi T, Iwasa K, Youdim MB, Naoi M.Yi H, et al.J Neural Transm (Vienna). 2006 Jan;113(1):21-32. doi: 10.1007/s00702-005-0299-z. Epub 2005 Apr 22.J Neural Transm (Vienna). 2006.PMID:15843867
- Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B.Tatton W, Chalmers-Redman R, Tatton N.Tatton W, et al.J Neural Transm (Vienna). 2003 May;110(5):509-15. doi: 10.1007/s00702-002-0827-z.J Neural Transm (Vienna). 2003.PMID:12721812Review.
- Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition.Youdim MB, Bar Am O, Yogev-Falach M, Weinreb O, Maruyama W, Naoi M, Amit T.Youdim MB, et al.J Neurosci Res. 2005 Jan 1-15;79(1-2):172-9. doi: 10.1002/jnr.20350.J Neurosci Res. 2005.PMID:15573406Review.
Cited by
- Monoamine oxidase B inhibitors for early Parkinson's disease.Macleod AD, Counsell CE, Ives N, Stowe R.Macleod AD, et al.Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD004898. doi: 10.1002/14651858.CD004898.pub2.Cochrane Database Syst Rev. 2005.PMID:16034956Free PMC article.Review.
- An inducer of VGF protects cells against ER stress-induced cell death and prolongs survival in the mutant SOD1 animal models of familial ALS.Shimazawa M, Tanaka H, Ito Y, Morimoto N, Tsuruma K, Kadokura M, Tamura S, Inoue T, Yamada M, Takahashi H, Warita H, Aoki M, Hara H.Shimazawa M, et al.PLoS One. 2010 Dec 9;5(12):e15307. doi: 10.1371/journal.pone.0015307.PLoS One. 2010.PMID:21151573Free PMC article.
- Salsolinol: an Unintelligible and Double-Faced Molecule-Lessons Learned from In Vivo and In Vitro Experiments.Kurnik-Łucka M, Panula P, Bugajski A, Gil K.Kurnik-Łucka M, et al.Neurotox Res. 2018 Feb;33(2):485-514. doi: 10.1007/s12640-017-9818-6. Epub 2017 Oct 23.Neurotox Res. 2018.PMID:29063289Free PMC article.Review.
- Mitochondria in neurodegenerative disorders: regulation of the redox state and death signaling leading to neuronal death and survival.Naoi M, Maruyama W, Yi H, Inaba K, Akao Y, Shamoto-Nagai M.Naoi M, et al.J Neural Transm (Vienna). 2009 Nov;116(11):1371-81. doi: 10.1007/s00702-009-0309-7.J Neural Transm (Vienna). 2009.PMID:19763773Review.
- Genomic and proteomic study to survey the mechanism of action of the anti-Parkinson's disease drug, rasagiline compared with selegiline, in the rat midbrain.Weinreb O, Amit T, Sagi Y, Drigues N, Youdim MB.Weinreb O, et al.J Neural Transm (Vienna). 2009 Nov;116(11):1457-72. doi: 10.1007/s00702-009-0225-x. Epub 2009 Apr 25.J Neural Transm (Vienna). 2009.PMID:19396396
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical